Pasithea reports promising phase 1 results for cancer drug

Pasithea Therapeutics (KTTA), despite an 80% stock decline over the past year, announced interim Phase 1 trial results for PAS-004, showing preliminary clinical activity in refractory solid tumors with MAPK pathway drivers. The trial demonstrated stable disease in 10 of 16 efficacy-evaluable patients, with tumor reductions observed in pancreatic cancer and melanoma patients; the drug also exhibited a favorable safety profile with no dose-limiting toxicities. CEO Tiago Reis Marques highlighted PAS-004's potential as a best-in-class MEK inhibitor, and InvestingPro data suggests strong liquidity and an undervalued stock based on fair value analysis, although overall financial health is rated as weak.

Analysis

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company with a market capitalization of approximately $6 million, has reported encouraging interim results from its Phase 1 trial of PAS-004, a next-generation macrocyclic MEK inhibitor. Despite its stock declining over 80% in the past year, the study, presented at ASCO 2025, demonstrated preliminary clinical activity in treating refractory solid tumors driven by the MAPK pathway. Notably, in 16 efficacy-evaluable patients, 10 achieved stable disease, with progression-free survival up to 159 days and overall survival up to 253 days. Specific tumor reductions included 9.8% in a stage 4 KRAS-mutated pancreatic cancer patient and 14.9% in a stage 4 BRAF-mutated melanoma patient, both remaining on treatment for over five months. The drug exhibited a favorable safety profile across six cohorts (21 patients dosed), with only mild treatment-related adverse events, no grade 3 or higher adverse events, and importantly, no dose-limiting toxicities (DLTs), permitting ongoing dose escalation, with the Safety Review Committee approving advancement to a 30mg capsule dosage. PAS-004 showed a dose-dependent pharmacokinetic profile, a half-life exceeding 60 hours suggesting prolonged target engagement, and achieved up to 91% inhibition of ERK phosphorylation. Preclinical data also suggests PAS-004 may offer better inflammatory response inhibition than selumetinib and notably, trial participants have not experienced rash, a common side effect with similar MEK inhibitors. Financially, InvestingPro analysis indicates strong liquidity with more cash than debt and a healthy current ratio of 3.84, supporting ongoing clinical development. However, this is juxtaposed with InvestingPro's assessment of weak overall financial health scores, though its Fair Value analysis suggests the stock is undervalued. The company is also advancing PAS-004 in a Phase 1/1b trial for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical trial data for PAS-004, particularly efficacy results from expanded cohorts and later-stage studies, given the promising but early-stage safety and preliminary efficacy signals in difficult-to-treat cancers.
• The significant stock depreciation alongside an 'undervalued' assessment from InvestingPro and strong liquidity position presents a speculative opportunity, heavily contingent on continued clinical success and prudent capital management, especially considering the noted 'weak overall financial health scores'.
• Consider the high-risk, high-reward profile inherent in a micro-cap biotechnology company like Pasithea; any investment should be sized appropriately within a diversified portfolio, acknowledging the binary nature of clinical trial outcomes and the company's dependence on PAS-004's progress.